In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe

As Alzheimer's disease pathogenesis is associated with the formation of insoluble aggregates of amyloid β-peptide, approaches allowing the direct, noninvasive visualization of plaque growth in vivo would be beneficial for biomedical research. Here we describe the synthesis and characterization of the near-infrared fluorescence oxazine dye AOI987, which readily penetrates the intact blood-brain barrier and binds to amyloid plaques. Using near-infrared fluorescence imaging, we demonstrated specific interaction of AOI987 with amyloid plaques in APP23 transgenic mice in vivo, as confirmed by postmortem analysis of brain slices. Quantitative analysis revealed increasing fluorescence signal intensity with increasing plaque load of the animals, and significant binding of AOI987 was observed for APP23 transgenic mice aged 9 months and older. Thus, AOI987 is an attractive probe to noninvasively monitor disease progression in animal models of Alzheimer disease and to evaluate effects of potential Alzheimer disease drugs on the plaque load.

[1]  B. Hyman,et al.  Imaging amyloid-beta deposits in vivo. , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  M. Staufenbiel,et al.  Extracellular amyloid formation and associated pathology in neural grafts , 2003, Nature Neuroscience.

[3]  Susan De Santi,et al.  Imaging is superior to cognitive testing for early diagnosis of Alzheimer’s disease , 2004, Neurobiology of Aging.

[4]  J. Pettegrew,et al.  Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease , 1994, Neurobiology of Aging.

[5]  R. Weissleder,et al.  Molecular imaging in drug discovery and development , 2003, Nature Reviews Drug Discovery.

[6]  N. Okamura,et al.  In vivo labeling of amyloid with BF-108 , 2004, Neuroscience Research.

[7]  Ralph Weissleder,et al.  In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.

[8]  R. Weissleder,et al.  In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. , 2004, Arthritis and rheumatism.

[9]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[10]  W. Klunk,et al.  Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. , 2004, Current pharmaceutical design.

[11]  G. Daves,et al.  Konig's Adducts of N-Alkyl(aryl)aminoethanols and Quinones. 3,4-Dihydro-4-alkyl(aryl)-8a-hydroxy-2H-1,4-benzoxazin-6(8aH)-ones , 1970 .

[12]  R. Nussbaum,et al.  Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.

[13]  Susumu Mori,et al.  Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging , 2004, Magnetic resonance in medicine.

[14]  G. Small,et al.  Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.

[15]  Brian J. Bacskai,et al.  Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.

[16]  Sung-Cheng Huang,et al.  2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[17]  Alan A. Wilson,et al.  11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. , 2003, Nuclear medicine and biology.

[18]  R. Weissleder,et al.  Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging , 2002, European Radiology.

[19]  Thomas Wisniewski,et al.  Molecular Targeting of Alzheimer's Amyloid Plaques for Contrast-Enhanced Magnetic Resonance Imaging , 2002, Neurobiology of Disease.

[20]  Vasilis Ntziachristos,et al.  Shedding light onto live molecular targets , 2003, Nature Medicine.

[21]  Jürgen Wolfrum,et al.  Detection of individual p53-autoantibodies by using quenched peptide-based molecular probes. , 2002, Angewandte Chemie.

[22]  G. Curran,et al.  Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. , 2004, Biochemistry.

[23]  Thomas Wisniewski,et al.  Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging , 2003, Magnetic resonance in medicine.

[24]  Brian J Bacskai,et al.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.

[25]  Vasilis Ntziachristos,et al.  A submillimeter resolution fluorescence molecular imaging system for small animal imaging. , 2003, Medical physics.

[26]  B. Hyman,et al.  Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative , 2002, Journal of neuropathology and experimental neurology.

[27]  Brian J Bacskai,et al.  Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[29]  B. Hyman,et al.  Imaging Amyloid-β Deposits In Vivo , 2002 .

[30]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[31]  W. Klunk,et al.  X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[32]  M. Staufenbiel,et al.  Styrylbenzoxazole Derivatives for In Vivo Imaging of Amyloid Plaques in the Brain , 2004, The Journal of Neuroscience.

[33]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[34]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[35]  Ralph Weissleder,et al.  Protease sensors for bioimaging , 2003, Analytical and bioanalytical chemistry.

[36]  G A Johnson,et al.  Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Umemiya,et al.  A Calcium-Dependent Feedback Mechanism Participates in Shaping Single NMDA Miniature EPSCs , 2001, The Journal of Neuroscience.

[38]  W. Klunk,et al.  Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. , 2001, Life sciences.

[39]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.